Sample Collection in Smoking Asthma

NCT ID: NCT01676467

Last Updated: 2013-01-08

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 23 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2012-09-30
• Study Completion Date: 2012-12-31

Brief Summary

This study will collect blood and sputum (phlegm) samples from subjects with asthma, smokers and normal healthy subjects, to compare the biological markers of disease and inflammation.

Conditions

Asthma

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: CROSS_SECTIONAL

Study Groups

Smoking asthma on steroids

Smokers with persistent asthma on background steroid therapy

No interventions assigned to this group

Smoking asthma steroid naïve

Smokers with persistent asthma, steroid naive

No interventions assigned to this group

asthma on steroids

Non-Smokers with persistent asthma on background steroid therapy

No interventions assigned to this group

asthma, steroid naïve

Non-smokers with persistent asthma, steroid naive

No interventions assigned to this group

Healthy smoking

Healthy smoking control subjects

No interventions assigned to this group

Healthy non-smoking

Healthy non-smoking control subjects

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Male or female, between 18 and 55 years of age, inclusive.
• no clinically significant abnormalities.
• able to produce an adequate induced sputum sample.
• no history of chronic respiratory disease including asthma.
• no history of allergic symptoms e.g., allergic rhinitis, eczema.
• No other acute illness in the 6 weeks prior to Visit 1.

Additional Inclusion Criterion for Healthy Smoking Subjects

• Be a smoker for >/= 1 year.

• No contraindications to the procedures in this study.
• Symptoms compatible with asthma for at least 6 months prior to screening
• Pre-bronchodilator FEV1 >/=50% predicted at Visit 1.
• clinically stable asthma for at least 6 weeks prior to Visit 1.
• No acute illness including asthma exacerbation requiring augmentation of therapy in the 6 weeks prior to Visit 1.
• on current asthma controller therapy for >/= 6 weeks prior to Visit 1.

Additional Inclusion for Steroid Naïve Asthmatics (smoking or non-smoking)

• Must not have received a regular course of inhaled or oral corticosteroids for at least 3 months prior to Visit 1.

Additional Inclusion for Smoking Asthmatics

• Be a smoker for >/= 1 year prior to Visit 1.

Exclusion Criteria

• History of any clinically significant medical illness or medical disorders.
• Diagnosis of chronic obstructive pulmonary disease (COPD), cystic fibrosis, or other significant respiratory disorder including significant occupational or environmental exposures with ongoing respiratory symptoms.
• bronchodilator response of >/=12% and at least 200 mL from baseline or an FEV1 value <85% of predicted value at Visit 1.
• positive urine pregnancy screening result.
• recent history (within previous 6 months) of alcohol or drug abuse.
• Positive urine toxicology screen for substances of abuse
• positive serology test for HIV antibodies, hepatitis B surface antigen (HBsAg), or hepatitis C virus antibody (anti-HCV) at Visit 1.
• Received an experimental antibody or biologic therapy within the 6 months prior to Visit 1, or received any other experimental therapy or new investigational agent within 60 days of Visit 1.
• Is an employee or family member of the investigator, study centre or Sponsor.
• Any condition that, in the opinion of the investigator, would complicate or compromise the study, or the well-being of the subject.
• Use of any antioxidants within 1 week of Visit 1 and throughout the study period.
• known allergies, hypersensitivity, or intolerance to short acting β-agonists (SABA).

Additional Exclusion Criterion for Healthy Non-smoking Subjects

• subject is a smoker (regular or irregular), or has smoked or used nicotine-containing products within the 6 months prior to Visit 1.

• Diagnosis of allergic bronchopulmonary aspergillosis (ABPA), allergic bronchopulmonary mycosis (ABPM), or occupational asthma.
• Diagnosis of COPD, cystic fibrosis, or other significant respiratory disorder including significant occupational or environmental exposures with ongoing respiratory symptoms.
• Use of theophylline, N-acetyl cysteine, or any other anti-oxidants within 1 week of Visit 1 and throughout the study period.
• positive test for tuberculosis at Visit 1.

Additional Exclusion Criterion for Non-smoking Asthmatic Subjects

• subject is a smoker (regular or irregular), or has smoked or used nicotine-containing products within the 6 months prior to Visit 1.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Respivert Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dr Garth Rapeport

Role: STUDY_DIRECTOR

Respivert Ltd

Locations

Harrow, Middlesex, United Kingdom

Countries

United Kingdom

Other Identifiers

ENA002

Identifier Type: -

Identifier Source: org_study_id